Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

4677 - Phase 3 KEYNOTE-585 Study of Chemotherapy (Chemo) + Pembrolizumab (Pembro) vs Chemo + Placebo as Neoadjuvant/Adjuvant Treatment for Patients (Pts) With Gastric or Gastroesophageal Junction (G/GEJ) Cancer


21 Oct 2018


Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology



Tumour Site

Gastric Cancer


Yung-Jue Bang


Annals of Oncology (2018) 29 (suppl_8): viii205-viii270. 10.1093/annonc/mdy282


Y. Bang1, E. van Cutsem2, C.S. Fuchs3, A. Ohtsu4, J. Tabernero5, D.H. Ilson6, W.J. Hyung7, V.E. Strong8, T.O. Goetze9, T. Yoshikawa10, L.H. Tang11, P.M.T. Hwang12, D. Adelberg12, K. Shitara4

Author affiliations

  • 1 Internal Medicine, Seoul National University Hospital, 110-744 - Seoul/KR
  • 2 Gastroenterology/digestive Oncology, University Hospitals Gasthuisberg Leuven and KU Leuven, Leuven/BE
  • 3 Medical Oncology, Yale Cancer Center, New Haven/US
  • 4 Gastrointestinal Oncology, National Cancer Center Hospital East, Chiba/JP
  • 5 Medical Oncology, Vall d'Hebron University Hospital, 08035 - Barcelona/ES
  • 6 Medical Oncology, Memorial Sloan Kettering Cancer Center, New York/US
  • 7 Surgery, Yonsei Cancer Hospital, Yonsei University Health System, Seoul/KR
  • 8 Surgery, Memorial Sloan Kettering Cancer Center, New York/US
  • 9 Institute Of Clinical Cancer Research, Institute of Clinical Cancer Research, UCT University Cancer Center, Frankfurt/DE
  • 10 Gastrointestinal Surgery, Kanagawa Cancer Center, Kanagawa/JP
  • 11 Pathology, Memorial Sloan Kettering Cancer Center, New York/US
  • 12 Medical Oncology, Merck & Co., Inc., Kenilworth/US

Abstract 4677


Pembro is FDA-approved for the treatment of pts with recurrent locally advanced or metastatic G/GEJ adenocarcinoma whose disease has progressed on or after ≥2 prior therapies and whose tumors express PD-L1 (combined positive score ≥1). Combining chemo with pembro in the neoadjuvant/adjuvant setting may benefit pts with locally advanced, resectable G/GEJ cancer. KEYNOTE-585 (NCT03221426) is a phase 3, randomized, double-blind study of chemo + pembro vs chemo + placebo as neoadjuvant/adjuvant treatment for locally advanced resectable G/GEJ cancer.

Trial design

Eligibility criteria are age ≥18 years; previously untreated, resectable G/GEJ adenocarcinoma (pts with Siewert type 1 tumors are eligible if initial treatment is planned perioperative chemo and resection), with no evidence of metastatic disease; planned surgery after preoperative chemo; adequate organ function; ECOG performance status 0/1; and no active autoimmune disease. Pts will be randomly assigned 1:1 to receive chemo + pembro (arm 1) or chemo + placebo (arm 2). Pts will receive neoadjuvant (preoperative) chemo + pembro every 3 weeks (Q3W) for 3 cycles or chemo + placebo Q3W for 3 cycles followed by surgery, then adjuvant chemo + pembro Q3W for 3 cycles or chemo + placebo Q3W for 3 cycles, then monotherapy with pembro or placebo Q3W for 11 cycles; overall treatment is up to 17 cycles. Chemo is cisplatin 80 mg/m2 IV on day 1 + either capecitabine 1000 mg/m2 orally twice daily × 14 days or 5-fluorouracil (5-FU) 800 mg/m2 IV daily × 5 days (investigator’s choice). Pembro 200 mg IV is given on day 1. Adjuvant monotherapy is pembro (arm 1) or placebo (arm 2). In a separate safety cohort, 5-FU 2600 mg/m2 IV + docetaxel 50 mg/m2 IV + oxaliplatin 85 mg/m2 IV + leucovorin 200 mg/m2 IV (FLOT) is being studied as a potential chemo option. Primary end points are overall survival, event-free survival per central review, and rate of pathologic complete response (no invasive disease and histologically negative nodes). Adverse events are graded and monitored for up to 90 days after treatment. Pts will be followed up for survival status. Planned enrollment is 860 pts.

Clinical trial identification

NCT03221426. Study start date was October 9, 2017.

Legal entity responsible for the study

Merck & Co., Inc.


Merck & Co., Inc.

Editorial Acknowledgement

Medical writing and/or editorial assistance was provided by Sarita Shaevitz, PhD, of the ApotheCom pembrolizumab team (Yardley, PA, USA).


Y-J. Bang: Consultancy: AstraZeneca, Novartis, Genentech/Roche, MSD, Pfizer, Bayer, BMS, Eli Lilly, Merck Serano, FivePrime, Taiho, Ono, ADC Therapeutics, GreenCross, Samyang Biopharm; Research funding (to institution): AstraZeneca, Novartis, Genentech/Roche, MSD, Merck Serano, Bayer, GSK, BMS, Pfizer, Eli Lilly, Boeringer-Ingelheim, MacroGenics, Boston Biomedical, FivePrime, CKD Pharma, Ono, Otsuka, Taiho, Takeda, BeiGene, Hanmi, Green Cross, Curis, Daiichi Sankyo, Astellas. E. Van Cutsem: Advisory board member: Bayer, Lilly, Roche; Servier Research funding: Amgen, Bayer, Boehringer, Celgene, Lilly, MSD, Merck, Novartis, Epsen, Roche, Sanofi, Servier. C.S. Fuchs: Advisory board member: Eli Lilly, Entrinsic Health, Genentech, Merck, Sanofi, Five Prime Therapeutics, Merrimack, Bayer, Agios, Taiho, Kew, Bain; Capital leadership: CytomX. A. Ohtsu: Research funding: BMS Consultant: Celgene. J. Tabernero: Advisory board member: Amgen, Bayer, Boehringer Ingelheim, Celgene, Chugai, Genentech, Lilly, MSD, Merck Serono, Novartis, Pfizer, Roche, Sanofi, Symphogen, Taiho, Takeda. D.H. Ilson: Advisory board member: Pieris, Astra-Zeneca, Astellas, BMS, Pfizer, Bayer, Lilly, Roche, Oncolys, Merck. W.J. Hyung: Stock ownership: Hutom; Advisory board member: Ethicon; Research funding: Medtronics T.O. Goetze: Advisory board member: MSD, Lilly, Shire, Celgene, Bayer, BMS; Speakers\' bureau: Lilly; Travel expenses: BMS, Lilly. T. Yoshikawa: Advisory board member: Novartis, MSD Oncology, Chugai Pharma; Research funding: Novartis, Chugai Pharma, Taiho Pharmaceutical, Yakult; Honoraria: Pharmaceutical, Abbott Nutrition, Takeda, Daiichi Sankyo, Ajinomoto, Ono Pharmaceutical, Nihonkayaku, Johnson & Johnson, Medtronic, Olympus, Lilly. P.M.T. Hwang: Employee, Stock ownership: Merck. D. Adelberg: Employee: Merck. K. Shitara: Advisory board member: Astellas Pharma, Lilly, Bristol-Myers Squibb, Takeda, Pfizer, Ono Pharmaceutical; Research funding: Dainippon Sumitomo Pharma, Lilly, MSD, Daiichi Sankyo, Taiho Pharmaceutical, Chugai Pharma, Ono Pharmaceutical; Honoraria: Novartis, AbbVie, Yakult. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.